$NKTR
NEKTAR THERAPEUTICS

2022 Q4 Form 10-Q Financial Statement

#000090670922000019 Filed on November 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $22.02M $23.63M
YoY Change -11.94% -5.2%
Cost Of Revenue $6.233M $4.972M
YoY Change 1.14% -6.38%
Gross Profit $15.79M $18.65M
YoY Change -16.22% -4.88%
Gross Profit Margin 71.7% 78.95%
Selling, General & Admin $21.94M $22.53M
YoY Change -31.74% -23.53%
% of Gross Profit 138.94% 120.81%
Research & Development $34.74M $33.59M
YoY Change -65.13% -67.62%
% of Gross Profit 220.01% 180.08%
Depreciation & Amortization $3.182M $2.677M
YoY Change -7.39% -26.05%
% of Gross Profit 20.15% 14.35%
Operating Expenses $56.68M $33.59M
YoY Change -43.1% -67.62%
Operating Profit -$40.89M -$54.30M
YoY Change -63.79% -52.2%
Interest Expense -$4.075M -$4.903M
YoY Change -51.07%
% of Operating Profit
Other Income/Expense, Net -$4.903M
YoY Change -69.35%
Pretax Income -$56.54M -$59.20M
YoY Change -61.18% -54.32%
Income Tax $3.144M -$155.0K
% Of Pretax Income
Net Earnings -$59.69M -$59.05M
YoY Change -59.02% -54.47%
Net Earnings / Revenue -271.03% -249.94%
Basic Earnings Per Share -$0.31
Diluted Earnings Per Share -$0.32 -$0.31
COMMON SHARES
Basic Shares Outstanding 188.0M shares 187.4M shares
Diluted Shares Outstanding 187.6M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $505.0M $546.4M
YoY Change -31.2% -40.68%
Cash & Equivalents $88.23M $105.8M
Short-Term Investments $416.8M $440.6M
Other Short-Term Assets $15.81M $22.51M
YoY Change -32.25% 8.57%
Inventory $19.20M $19.06M
Prepaid Expenses
Receivables $5.981M $11.53M
Other Receivables $0.00 $0.00
Total Short-Term Assets $546.0M $599.5M
YoY Change -31.37% -39.21%
LONG-TERM ASSETS
Property, Plant & Equipment $32.45M $36.80M
YoY Change -46.37% -37.44%
Goodwill $76.50M $76.50M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change -100.0% -100.0%
Other Assets $2.245M $2.323M
YoY Change -18.19% 25.98%
Total Long-Term Assets $164.6M $181.5M
YoY Change -48.81% -37.64%
TOTAL ASSETS
Total Short-Term Assets $546.0M $599.5M
Total Long-Term Assets $164.6M $181.5M
Total Assets $710.6M $781.0M
YoY Change -36.39% -38.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.98M $5.329M
YoY Change 33.17% -77.48%
Accrued Expenses $55.22M $78.66M
YoY Change -26.81% -32.37%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $68.20M $83.99M
YoY Change -19.95% -39.99%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.551M $3.054M
YoY Change 110.22% -21.06%
Total Long-Term Liabilities $7.551M $3.054M
YoY Change 110.22% -21.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $68.20M $83.99M
Total Long-Term Liabilities $7.551M $3.054M
Total Liabilities $344.0M $368.8M
YoY Change -21.41% -22.48%
SHAREHOLDERS EQUITY
Retained Earnings -$3.201B -$3.142B
YoY Change 13.0% 16.9%
Common Stock $3.575B $3.562B
YoY Change 1.65% 1.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $366.6M $412.2M
YoY Change
Total Liabilities & Shareholders Equity $710.6M $781.0M
YoY Change -36.39% -38.85%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$59.69M -$59.05M
YoY Change -59.02% -54.47%
Depreciation, Depletion And Amortization $3.182M $2.677M
YoY Change -7.39% -26.05%
Cash From Operating Activities -$57.70M -$82.89M
YoY Change -61.92% -18.04%
INVESTING ACTIVITIES
Capital Expenditures $512.0K -$181.0K
YoY Change -108.68% -93.84%
Acquisitions
YoY Change
Other Investing Activities $40.53M $111.6M
YoY Change -67.86% 5198.01%
Cash From Investing Activities $40.01M $111.4M
YoY Change -66.71% -13521.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 103.0K 0.000
YoY Change -95.96% -100.0%
NET CHANGE
Cash From Operating Activities -57.70M -82.89M
Cash From Investing Activities 40.01M 111.4M
Cash From Financing Activities 103.0K 0.000
Net Change In Cash -17.59M 28.51M
YoY Change -38.91% -129.0%
FREE CASH FLOW
Cash From Operating Activities -$57.70M -$82.89M
Capital Expenditures $512.0K -$181.0K
Free Cash Flow -$58.22M -$82.71M
YoY Change -60.03% -15.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0000906709
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-24006
dei Entity Registrant Name
EntityRegistrantName
NEKTAR THERAPEUTICS
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3134940
dei Entity Address Address Line1
EntityAddressAddressLine1
455 Mission Bay Boulevard South
dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94158
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
482-5300
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
NKTR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
187954482 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
105758000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25218000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
15801000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
440629000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
708737000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11532000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
22492000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
19057000 usd
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
22507000 usd
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
23333000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
599483000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
795581000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
64828000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36803000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
60510000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
65896000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
117025000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
83989000 usd
CY2022Q3 us-gaap Goodwill
Goodwill
76501000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
76501000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2323000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2744000 usd
CY2022Q3 us-gaap Assets
Assets
781006000 usd
CY2021Q4 us-gaap Assets
Assets
1117189000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5329000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9747000 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
24392000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15735000 usd
CY2022Q3 nktr Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
20461000 usd
CY2021Q4 nktr Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
26809000 usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
15299000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
15468000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18508000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
17441000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
85200000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
116145000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
125736000 usd
CY2022Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 usd
CY2021Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
27726000 usd
CY2022Q3 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
165595000 usd
CY2021Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
195427000 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3054000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3592000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
368783000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
437681000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
15402000 usd
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
187954000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
185468000 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
19000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
19000 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3561878000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3516641000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8169000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4157000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3141505000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2832995000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
412223000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
679508000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
781006000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1117189000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23625000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24921000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
70032000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
76898000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4972000 usd
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5311000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
18734000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33590000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
103738000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
183583000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
300655000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22534000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29468000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
70394000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
90702000 usd
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
16830000 usd
CY2021Q3 us-gaap Restructuring Charges
RestructuringCharges
0 usd
us-gaap Restructuring Charges
RestructuringCharges
124350000 usd
us-gaap Restructuring Charges
RestructuringCharges
0 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
77926000 usd
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
138517000 usd
us-gaap Costs And Expenses
CostsAndExpenses
393729000 usd
us-gaap Costs And Expenses
CostsAndExpenses
410091000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-54301000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-113596000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-323697000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-333193000 usd
CY2022Q3 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0 usd
CY2021Q3 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-3328000 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
33427000 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-7640000 usd
CY2022Q3 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
6953000 usd
CY2021Q3 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
12801000 usd
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
21710000 usd
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
39186000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2050000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
131000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3541000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-44438000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2388000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4903000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15998000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15258000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-59204000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-129594000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-308439000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-377631000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-155000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
112000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
71000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
561000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-59049000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-129706000 usd
us-gaap Net Income Loss
NetIncomeLoss
-308510000 usd
us-gaap Net Income Loss
NetIncomeLoss
-378192000 usd
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.07
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
187641000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
187641000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
184110000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
184110000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
186767000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
186767000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
182736000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
182736000 shares
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-59049000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-129706000 usd
us-gaap Net Income Loss
NetIncomeLoss
-308510000 usd
us-gaap Net Income Loss
NetIncomeLoss
-378192000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
490000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-176000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2589000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1006000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-468000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
13000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1423000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-262000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
22000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-163000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4012000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1268000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59027000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-129869000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-312522000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-379460000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1077295000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
17106000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23898000 usd
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-123793000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
994506000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
12553000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23714000 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-125798000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
904975000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1777000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24657000 usd
us-gaap Profit Loss
ProfitLoss
-378192000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-129869000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
801540000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
679508000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
188000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20961000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-92768000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
607889000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
467000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11103000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-160727000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
458732000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
0 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12518000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59027000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
412223000 usd
us-gaap Profit Loss
ProfitLoss
-308510000 usd
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
52167000 usd
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
58667000 usd
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
21710000 usd
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
39186000 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
33427000 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-7640000 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
4951000 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
11497000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
44582000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
72269000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
9848000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
10710000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
58521000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
372000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-5677000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10960000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9895000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3256000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
38000 usd
nktr Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
1423000 usd
nktr Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
-2932000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-4861000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-814000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4184000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1247000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
8657000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
18350000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-7055000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-4442000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-246304000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-261122000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
295439000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
816049000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
626424000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
902687000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
5035000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5164000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9093000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
325821000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
82580000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
655000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
31436000 usd
us-gaap Proceeds From Derivative Instrument Financing Activities
ProceedsFromDerivativeInstrumentFinancingActivities
750000 usd
us-gaap Proceeds From Derivative Instrument Financing Activities
ProceedsFromDerivativeInstrumentFinancingActivities
2250000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1405000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
33686000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-382000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-82000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
80540000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-144938000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25218000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
198955000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105758000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54017000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1057000 usd
CY2022Q3 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
546400000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Significant ConcentrationsOur customers are primarily pharmaceutical companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements.We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, various factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer’s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if various factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.
CY2021Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2022Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
nktr Debt Investment Maturity Term
DebtInvestmentMaturityTerm
P1Y
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
105758000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25218000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
440629000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
708737000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
64828000 usd
CY2022Q3 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
546387000 usd
CY2021Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
798783000 usd
nktr Debt Investment Maximum Maturity Period
DebtInvestmentMaximumMaturityPeriod
P2Y
CY2022Q3 us-gaap Cash
Cash
8341000 usd
CY2021Q4 us-gaap Cash
Cash
1250000 usd
CY2022Q3 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
546387000 usd
CY2021Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
798783000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
700000 usd
CY2022Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2053000 usd
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3166000 usd
CY2022Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
15312000 usd
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
9342000 usd
CY2022Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1692000 usd
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3293000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
19057000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
15801000 usd
CY2022Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
0 usd
nktr Royalty Monetization Proceeds
RoyaltyMonetizationProceeds
274000000 usd
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
-385618000 usd
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
265983000 usd
nktr Partial Repayment Of Royalty Sale Proceeds
PartialRepaymentOfRoyaltySaleProceeds
10000000 usd
nktr Gain Loss On Revaluation Of Liabilities Related To The Sale Of Future Royalties Gross
GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross
23522000 usd
CY2022Q3 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
167887000 usd
CY2022Q3 nktr Liabilities On Sale Of Future Royalties Unamortized Transaction Costs
LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
2292000 usd
CY2022Q3 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
165595000 usd
CY2022Q3 us-gaap Business Exit Costs1
BusinessExitCosts1
8530000 usd
us-gaap Business Exit Costs1
BusinessExitCosts1
28938000 usd
CY2022Q3 us-gaap Severance Costs1
SeveranceCosts1
2077000 usd
us-gaap Severance Costs1
SeveranceCosts1
29827000 usd
CY2022Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
1200000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
58521000 usd
CY2022Q3 us-gaap Loss On Contract Termination
LossOnContractTermination
5023000 usd
us-gaap Loss On Contract Termination
LossOnContractTermination
7064000 usd
CY2022Q3 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
16830000 usd
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
124350000 usd
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
53401000 usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
5120000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
58521000 usd
CY2022Q3 us-gaap Impairment Of Leasehold
ImpairmentOfLeasehold
1200000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36803000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
60510000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12518000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24657000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
44582000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
72269000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
5890000 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
397000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
6019000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
674000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.23
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.36
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.72
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19575000 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17634000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20809000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18454000 shares

Files In Submission

Name View Source Status
0000906709-22-000019-index-headers.html Edgar Link pending
0000906709-22-000019-index.html Edgar Link pending
0000906709-22-000019.txt Edgar Link pending
0000906709-22-000019-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nktr-20220930.htm Edgar Link pending
nktr-20220930.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nktr2022-09x30xexx311.htm Edgar Link pending
nktr2022-09x30xexx312.htm Edgar Link pending
nktr2022-09x30xexx321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
nktr-20220930_cal.xml Edgar Link unprocessable
nktr-20220930_lab.xml Edgar Link unprocessable
nktr-20220930_pre.xml Edgar Link unprocessable
nktr-20220930_htm.xml Edgar Link completed
Show.js Edgar Link pending
nktr-20220930_def.xml Edgar Link unprocessable